Malignant brain tumors of glial origin have proven relatively refractory to current chemotherapy, primarily because of undesirable toxicity to normal tissues. A major objective of oncologic therapeutics is to enhance neoplastic cytotoxicity and minimize undesirable effects to normal cells. One avenue to achieve such a goal employs the novel technology of in vivo gene transfer to endow tumor cells with the capability of converting prodrugs into their active anticancer metabolites. The most widely effective chemotherapeutic agents for brain tumors are the alkylating nitrosoureas. The mustard-like compounds are another class of DNA- alkylating agents. Prodrugs for each of these agents exist: 1) cyclophosphamide (CPA) is an inactive lipophilic compound which can be activated by a cytochrome P450 enzyme (cytochrome P450 2B1) into phosphoramide mustard (PM), a potent DNA-alkylator; 2) Methylpropylchloronitrosourea (MPCNU) is a prodrug which can also be activated by cytochrome P450 enzymes (2E1 and possibly, 2B1) into the active anticancer metabolite, PrCNU. Viral vectors, based on retroviruses and on herpes simplex virus (HSV), will thus be engineered to transfer that rat cytochrome P450 2B1 (or 2E1) gene(s) into rat brain tumor cells. In vitro studies will determine the acquisition of CPA-and MPCNU- susceptibility after infection with either vector (specific aims 1 and 2). An animal model of brain tumors will then be employed to determine whether the above gene therapy strategy shows therapeutic effectiveness. This will entail volumetric analyses of tumor regression, studies on animal survival, histopathologic correlates of regression, studies on toxic effects to normal tissues, assays of CPA and MPCNU metabolites in the blood of treated animals as well as in brain and tumor tissue (specific aims 3 and 4). These studies should provide the necessary information to justify a phase I/II trial of therapy in humans afflicted with malignant glial tumors using genes that will activate alkylating prodrugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA069246-04S1
Application #
6396881
Study Section
Project Start
1999-08-06
Project End
2000-05-31
Budget Start
Budget End
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Ricklefs, Franz L; Alayo, Quazim; Krenzlin, Harald et al. (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4:eaar2766
Park, Jongmin; Im, Hyungsoon; Hong, Seonki et al. (2018) Analyses of Intravesicular Exosomal Proteins Using a Nano-Plasmonic System. ACS Photonics 5:487-494
Antoury, Layal; Hu, Ningyan; Balaj, Leonora et al. (2018) Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun 9:3906
Zhou, Shuang; Appleman, Vicky A; Rose, Christopher M et al. (2018) Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Sci Alliance 1:e201800029
Min, Jouha; Nothing, Maria; Coble, Ben et al. (2018) Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis. ACS Nano 12:3378-3384
Lee, Kyungheon; Fraser, Kyle; Ghaddar, Bassel et al. (2018) Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano 12:494-503
ReƔtegui, Eduardo; van der Vos, Kristan E; Lai, Charles P et al. (2018) Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nat Commun 9:175
Speranza, Maria-Carmela; Passaro, Carmela; Ricklefs, Franz et al. (2018) Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol 20:225-235
Boussiotis, Vassiliki A; Charest, Alain (2018) Immunotherapies for malignant glioma. Oncogene 37:1121-1141
Sahin, Ayguen; Sanchez, Carlos; Bullain, Szofia et al. (2018) Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS One 13:e0199414

Showing the most recent 10 out of 223 publications